{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:05:56Z","timestamp":1772186756428,"version":"3.50.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T00:00:00Z","timestamp":1365724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061160","type":"journal-article","created":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T17:05:12Z","timestamp":1365786312000},"page":"e61160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00130286","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marshall J.","family":"Glesby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanine","family":"Albu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsis","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Engelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varalakshmi","family":"Muthukrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Kotler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,4,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"S Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2011.151","article-title":"Management of the metabolic effects of HIV and HIV drugs","volume":"8","author":"TT Brown","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"K Brinkman","year":"1999","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/cir324","article-title":"Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s","volume":"53","author":"GA McComsey","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jc.2004-1342","article-title":"Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy","volume":"90","author":"P Koutkia","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","first-page":"504","article-title":"Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy","volume":"86","author":"P Rietschel","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00042560-200208010-00002","article-title":"Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection","volume":"30","author":"ES Engelson","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QAI.0b013e31804a7f68","article-title":"Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy","volume":"45","author":"C Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00126334-200403010-00004","article-title":"Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients","volume":"35","author":"DP Kotler","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.qai.0000243108.26136.66","article-title":"Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum","volume":"43","author":"DP Kotler","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1172\/JCI119870","article-title":"Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation","volume":"100","author":"M Adams","year":"1997","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)","volume":"13","author":"L Slama","year":"2008","journal-title":"Antivir Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/QAD.0b013e328339e274","article-title":"Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens","volume":"24","author":"M Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ajcn\/69.6.1162","article-title":"Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging","volume":"69","author":"ES Engelson","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.ijo.0800660","article-title":"Selection of anthropometric indicators for classification of abdominal fatness\u2013a critical review","volume":"22","author":"A Molarius","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"A Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1210\/jcem.86.8.7785","article-title":"The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation","volume":"86","author":"JC Lo","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/diab.43.11.1365","article-title":"Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design","volume":"43","author":"GM Steil","year":"1994","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/152091503322641060","article-title":"MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test","volume":"5","author":"RC Boston","year":"2003","journal-title":"Diabetes Technol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajcn\/41.2.363","article-title":"A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids","volume":"41","author":"HC Lukaski","year":"1985","journal-title":"Am J Clin Nutr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ajcn\/50.6.1290","article-title":"Measurement of extracellular water volume by bromide ion chromatography","volume":"50","author":"WW Wong","year":"1989","journal-title":"Am J Clin Nutr"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"MC Gelato","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref23","first-page":"676","article-title":"Some Aspects of the Rank Transformation in Analysis of Variance Problems","volume":"7","author":"R Iman","year":"1982","journal-title":"Proceedings of the SAS User's Group Intl"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"KF Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","article-title":"Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure","volume":"50","author":"S Nielsen","year":"2001","journal-title":"Diabetes"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1210\/jcem.86.12.8096","article-title":"Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults","volume":"86","author":"M Segerlantz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"AB Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s001250100031","article-title":"Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients","volume":"44","author":"Y Miyazaki","year":"2001","journal-title":"Diabetologia"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/hct0904-254","article-title":"Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone","volume":"9","author":"DC Macallan","year":"2008","journal-title":"HIV Clin Trials"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Y Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/diacare.22.6.908","article-title":"Effect of troglitazone on body fat distribution in type 2 diabetic patients","volume":"22","author":"Y Mori","year":"1999","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0026-0495(99)90122-1","article-title":"Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes","volume":"48","author":"T Kawai","year":"1999","journal-title":"Metabolism"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0168-8227(01)00319-9","article-title":"Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation\u2013double-blind placebo-controlled trial","volume":"54","author":"T Nakamura","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"SR Smith","year":"2005","journal-title":"Metabolism"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pctr.0020021","article-title":"Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial","volume":"2","author":"H Attallah","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","article-title":"The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials","volume":"10","author":"SH Sheth","year":"2010","journal-title":"BMC Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1310\/hct1101-39","article-title":"A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy","volume":"11","author":"JM Raboud","year":"2010","journal-title":"HIV Clin Trials"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.aids.0000180099.35146.30","article-title":"A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation","volume":"19","author":"J Falutz","year":"2005","journal-title":"AIDS"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","volume":"357","author":"J Falutz","year":"2007","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","article-title":"Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data","volume":"95","author":"J Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension","volume":"53","author":"J Falutz","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1345\/aph.1Q400","article-title":"Rosiglitazone, myocardial ischemic risk, and recent regulatory actions","volume":"46","author":"CA Bourg","year":"2012","journal-title":"Ann Pharmacother"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"SE Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"SE Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"S Singh","year":"2007","journal-title":"JAMA"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T19:58:24Z","timestamp":1688155104000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061160"}},"subtitle":[],"editor":[{"given":"Jianping","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,12]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061160","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006638.793477602","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,12]]}}}